Article Sidebar
Published:
Apr 19, 2023Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of Jinlida granule on glycolipid metabolism, oxidative stress, and inflammatory factors in type 2 diabetes mellitus patients with non alcoholic fatty liver disease
Abstract
Purpose: To investigate the effect of Jinlida granule on glycolipid metabolism, oxidative stress, and inflammatory factors in type 2 diabetes mellitus (T2DM) patients with non-alcoholic fatty liver disease (NAFLD).
Methods: A total of 132 T2DM patients with NAFLD were equally and randomly divided into study and control groups. Patients in the control group were treated with non-drug therapy including routine diet control, exercise, alcohol avoidance, and drug therapy (using blood glucose and lipid lowering drugs). The study group was treated with Jinlida granule in addition to other measures used in the control group. Blood glucose, blood lipid, and liver function parameters were compared after treatment. Nesfatin-1, oxidative stress, inflammatory factors, liver fat content, and degree of fibrosis were assessed. The efficacy and potential mechanism of Jinlida granule in the patients were assessed.
Results: Blood glucose, lipid, and liver function parameters in the study group were lower than in the control group following treatment. Nesfatin-1, GSH-Px, and adiponectin levels were higher, while MDA, TNF-α, liver fat, LSM and CAP levels were lower than in the control group (p < 0.05). The response rate of the study group was 96.97 %, which was higher than the 87.88 % in the control group (p < 0.05). The incidence of adverse drug reactions in the two groups during treatment was comparable (p > 0.05).
Conclusion: Jinlida granule exerts positive effect on T2DM patients with NAFLD. Thus, Jinlida granule has potentials for application as an adjuvant in the treatment of T2DM with NAFLD.
